Growth & profitability
- Revenue has grown 25.6% per year over the past 5 years.
- Operating margin has expanded, at 20.4% in the latest year.
ANAB Financials Anaptysbio, Inc
11 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $235M | -$13M | 0.0% | 20.4% | $20M | — | $238M |
| 2024 | $91M | -$145M | 0.0% | -125.9% | -$136M | — | $123M |
| 2023 | $17M | -$164M | 0.0% | -958.3% | -$122M | — | $36M |
| 2022 | $10M | -$129M | 0.0% | -1119.4% | -$74M | — | $71M |
| 2021 | $63M | -$58M | 0.0% | -89.9% | -$47M | — | $496M |
| 2020 | $75M | -$20M | 0.0% | -31.8% | -$15M | — | $250M |
| 2019 | $8M | -$97M | 0.0% | -1342.9% | -$70M | — | $171M |
| 2018 | $5M | -$62M | 0.0% | -1334.4% | -$50M | — | $114M |
| 2017 | $10M | -$30M | 0.0% | -287.8% | -$20M | — | $81M |
| 2016 | — | -$4M | — | — | -$9M | — | $51M |
| 2015 | — | -$5M | — | — | -$10M | — | — |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $26M | -$53M | 0.0% | -135.5% | -$26M | — | $248M |
| Dec '25 | $108M | $50M | 0.0% | 61.8% | $98M | — | $238M |
| Sep '25 | $76M | $15M | 0.0% | 45.5% | -$27M | — | $110M |
| Jun '25 | $22M | -$39M | 0.0% | -117.5% | -$40M | — | $44M |
| Mar '25 | $28M | -$39M | 0.0% | -99.2% | -$11M | — | $99M |
| Dec '24 | $43M | -$22M | 0.0% | -22.4% | -$67M | — | $123M |
| Sep '24 | $30M | -$33M | 0.0% | -75.8% | -$10M | — | $192M |
| Jun '24 | $11M | -$47M | 0.0% | -367.5% | -$21M | — | $72M |
| Mar '24 | $7M | -$44M | 0.0% | -587.8% | -$37M | — | $54M |
| Dec '23 | $9M | -$42M | 0.0% | -467.9% | -$35M | — | $36M |
| Sep '23 | $3M | -$37M | 0.0% | -1137.2% | -$37M | — | $26M |
| Jun '23 | $3M | -$40M | 0.0% | -1160.2% | -$26M | — | $35M |
| Mar '23 | $1M | -$44M | 0.0% | -3231.5% | -$25M | — | $95M |
| Dec '22 | $7M | -$26M | 0.0% | -381.5% | -$11M | — | $71M |
| Sep '22 | $1M | -$34M | 0.0% | -2291.8% | -$18M | — | $59M |
| Jun '22 | $1M | -$33M | 0.0% | -2286.1% | -$24M | — | $72M |
| Mar '22 | $970000 | -$36M | 0.0% | -3273.1% | -$21M | — | $166M |
| Dec '21 | $1M | -$33M | 0.0% | -3081.8% | -$25M | — | $496M |
| Sep '21 | $21M | -$7M | 0.0% | -32.4% | -$7M | — | $336M |
| Jun '21 | $30M | -$429000 | 0.0% | -1.8% | $9M | — | $332M |
Valuation over time
How the market has priced ANAB against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has fallen from 61.4× (Mar '23) to 7.4× (Jun '26).
P/S
Frequently asked questions
Is ANAB growing its revenue and profit?
Over the past 5 years, Anaptysbio, Inc's revenue has grown 25.6% per year. These are computed facts, not advice.
How much debt does ANAB have?
As of FY2025, Anaptysbio, Inc reported — of total debt against $238M of cash.
What is ANAB's profit margin?
In FY2025, gross margin was —, operating margin 20.4%, and net margin -5.6%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.